

***Supplementary Information***

**PPh<sub>3</sub>-catalyzed intramolecular cyclization of hydroxypropargylamides:  
Synthesis of structurally diverse morpholinone derivatives**

Moumita Paira

Department of Chemistry, Panskura Banamali College, Panskura, Panskura R.S. 721 152, West Bengal, India  
E-mail: paira\_moumita@yahoo.co.in

*Received 31 January 2022; accepted (revised) 15 March 2022*

## TABLE OF CONTENTS

- [1] Experimental Section
- [2] General Procedure for the Synthesis of **5a–o**.
- [3] General Procedure for the Synthesis of **6a–o**.
- [4] Complete Structure Characterization and 1D & 2D all spectral data of **6a** and spectral data of **6b–6o**.
- [5] Synthesis and spectral data of **5a–5o**


## 1. EXPERIMENTAL SECTION

### General Experimental Information

Unless otherwise specified, all reactions were carried out under air atmosphere in oven-dried round-bottom flasks and the heating reactions were performed in oil bath. All commercially available reagents were purchased from commercial sources and were used without further purification. All reactions were monitored by thin layer chromatography over silica gel-coated TLC plates. Thin-layer chromatography (TLC) was performed on 60 F254 silica gel, pre-coated on aluminum plates, and revealed with either a UV lamp( $\lambda_{\text{max}} = 254$  nm), a specific color reagent (iodine vapors). Silica gel 230-400 mesh was used for column chromatography.  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded on Bruker AV400 MHz spectrometer. Chemical shifts  $\delta$  are given in ppm relative to the residual signals of tetramethylsilane in  $\text{CDCl}_3$  for  $^1\text{H}$  and  $^{13}\text{C}$  NMR. Coupling constants are given in hertz. The HRMS spectra were recorded as ESI-HRMS on Q-TOF mass spectrometer.

Commercially available grades of organic solvents of adequate purity are used in all reactions.

## 2. General Procedure for the Synthesis of **5a–o**.




To solution of aromatic aldehyde **2** (1.0 mmol) in methanol (10 ml) were added with 1,2-aminoalcohol (**1**, 1.0 mmol) and the mixture was stirred at room temperature for 1h. Then, acid **4** (1 mmol) was added, and stirring was continued, followed by addition of isocyanides **3** (1 mmol). The mixture was stirred for 10-24 hrs at room temperature. Reaction was monitored by TLC (*n*-hexane/EtOAc 2:1). After the completion of the reaction, the reaction mixture was concentrated under reduced pressure and purified by column chromatography on silica gel (eluent:hexane/EtOAc) to afford Ugi-hydroxypropargyl amides adduct (**5a–o**).

## 3. General Procedure for the Synthesis of Compounds **6a–o**.

To the stirred solution of Ugi- hydroxypropargylamides adduct **5a–o** (1 mmole) in 5 ml of EtOH was added triphenylphosphine (30%) at room temperature. The reaction mixture was stirred at 80 °C for 10 h until the reaction reached completion as evidenced by TLC. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure and purified by column chromatography on silica gel (eluent:hexane/EtOAc) to afford morpholinone products (**6a–o**).

Spectral data and HRMS of **6a-6o**





<sup>1</sup>H NMR spectrum of **6a** (400MHz, CDCl<sub>3</sub>)




— 168.64  
 > 160.60  
 < 159.20  
 — 144.50  
 // 134.46  
 // 130.57  
 // 129.92  
 // 128.27  
 // 127.61  
 — 126.16  
 — 114.90  
 — 113.28


— 77.31  
 < 77.05  
 < 76.80  
 — 64.64  
 > 63.55  
 > 59.83  
 — 51.85  
 — 43.11  
 — 28.71  
 — 14.79




<sup>13</sup>C NMR spectrum of **6a** (100MHz, MHz, CDCl<sub>3</sub>)





DEPT-135 spectrum of **6a** (100MHz,MHz,CDCl<sub>3</sub>)



2D-COSY spectrum of **6a** (400MHz,MHz,CDCl<sub>3</sub>)



2D-HSQC spectrum of **6a** (400 MHz, MHz, CDCl<sub>3</sub>)



2D-NOESY spectrum of **6a** (400MHz, CDCl<sub>3</sub>)

## SAIF [HRMS Report]

Data File:

HRMS21I22MAR12

Original Data Path:

D:\INTERNAL NEW\2021\Mar  
2021

Sample ID:

PKM-22R

Sample Name:

Acquisition Date:

03/22/21 01:05:23 PM

Run Time(min):

0.00



Vial:

CStd1-01:12

Injection Volume(μl):


1.00

HRMS21I22MAR12 #33-66 RT: 0.25-0.50 AV: 34 SB: 1 0.00 NL: 3.85E6  
T: FTMS + p ESI Full ms [150.00-1000.00]




m/z:  $[M + H]^+$  Calcd for  
 $C_{25}H_{31}N_2O_4$  423.2278;  
Found 423.2279.

HRMS of compound **6a**



$^1\text{H}$  NMR spectrum of **6b** (400MHz,  $\text{CDCl}_3$ )






$^{13}\text{C}$  NMR spectrum of **6b** (100 MHz, MHz,  $\text{CDCl}_3$ )


## SAIF [HRMS Report]

Data File:	HRMS21I23MAR09	Original Data Path:	D:\INTERNAL NEW\2021\Mar 2021
Sample ID:	PKM-M-23R	Sample Name:	
Acquisition Date:	03/23/21 11:46:44 AM	Run Time(min):	0.00
Vial:	CStk1-01:9	Injection Volume(μl):	1.00


HRMS21I23MAR09 #32-64 RT: 0.25-0.50 AV: 33 SB: 1 0.00 NL: 3.44E5  
T: FTMS + p ESI Full ms [150.00-1000.00]



HRMS of compound **6b**



<sup>1</sup>H NMR spectrum of **6c** (400MHz, CDCl<sub>3</sub>)





$^{13}\text{C}$  NMR spectrum of **6c** (100 MHz, MHz,  $\text{CDCl}_3$ )

## SAIF [HRMS Report]


Data File: HRMS21I17MAR39 Original Data Path: D:\INTERNAL NEW\2021\Mar 2021  
Sample ID: PKM-M-17R Sample Name:  
Acquisition Date: 03/17/21 12:19:32 PM Run Time(min): 0.00  
Vial: CSkl-01:39 Injection Volume(μl): 1.00

HRMS21I17MAR39 #32-66 RT: 0.25-0.50 AV: 35 SB: 1 0.00 NL: 1.24E7  
T: FTMS + p ESI Full ms [150.00-1000.00]




m/z:[M+H]<sup>+</sup>Calcd for C<sub>24</sub>H<sub>29</sub>N<sub>2</sub>O<sub>3</sub>: 393.2173; Found: 393.2172.

HRMS of compound **6c**



<sup>1</sup>H NMR spectrum of **6d** (400MHz,CDCl<sub>3</sub>)





$^{13}\text{C}$  NMR spectrum of **6d** (100 MHz, MHz,  $\text{CDCl}_3$ )

### SAIF [HRMS Report]

Data File:	HRMS21I17MAR38	Original Data Path:	D:\INTERNAL NEW\2021\Mar 2021
Sample ID:	PKM-M-12R	Sample Name:	
Acquisition Date:	03/17/21 12:17:33 PM	Run Time(min):	0.00
Vial:	CStk1-01:38	Injection Volume(µl):	1.00


HRMS21I17MAR38 #32-66 RT: 0.25-0.50 AV: 35 SB: 1 0.00 NL: 8.10E6  
T: FTMS + p ESI Full ms [150.00-1000.00]




$m/z:[M+H]^+$  Calcd for  $C_{25}H_{29}N_2O_3$ : 405.2173;  
Found: 405.2171.

HRMS of compound **6d**





<sup>1</sup>H NMR spectrum of **6e** (400MHz,CDCl<sub>3</sub>)





$^{13}\text{C}$  NMR spectrum of **6e** (100MHz,  $\text{CDCl}_3$ )

## SAIF [HRMS Report]


Data File: HRMS21I17MAR37 Original Data Path: D:\INTERNAL NEW\2021\Mar 2021  
Sample ID: PKM-M-10R Sample Name:  
Acquisition Date: 03/17/21 12:15:34 PM Run Time(min): 0.00  
Vial: CStk1-01:37 Injection Volume(µl): 1.00

HRMS21I17MAR37 #32-65 RT: 0.25-0.50 AV: 34 SB: 1 0.01 NL: 1.89E6  
T: FTMS + c ESI Full ms [100.00-750.00]




m/z:[M+H]<sup>+</sup>Calcd for C<sub>23</sub>H<sub>26</sub>FN<sub>2</sub>O<sub>3</sub>: 397.1922;  
Found: 397.1922.

HRMS of compound **6e**



<sup>1</sup>H NMR spectrum of **6f** (400MHz, CDCl<sub>3</sub>)







$^{13}\text{C}$  NMR spectrum of **6f** (100MHz, MHz,  $\text{CDCl}_3$ )

## SAIF [HRMS Report]


Data File:	HRMS21I19MAR10	Original Data Path:	D:\INTERNAL NEW\2021\Mar 2021
Sample ID:	PKM-M-21R	Sample Name:	
Acquisition Date:	03/19/21 11:20:10 AM	Run Time(min):	0.00
Vial:	CStk1-01:10	Injection Volume(μl):	1.00

HRMS21I19MAR10 #32-66 RT: 0.25-0.50 AV: 35 SB: 1 0.00 NL: 7.01E6  
T: FTMS + p ESI Full ms [150.00-1000.00]




m/z:[M+H]<sup>+</sup>Calcd for C<sub>23</sub>H<sub>25</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub>: 415.1828;  
Found: 415.1828.

HRMS of compound **6f**



$^1\text{H}$  NMR spectrum of **6g** (400MHz,  $\text{CDCl}_3$ )





<sup>13</sup>C NMR spectrum of **6g** (100MHz, MHz, CDCl<sub>3</sub>)


## SAIF [HRMS Report]

Data File:	HRMS21I22MAR11	Original Data Path:	D:\INTERNAL NEW\2021\Mar 2021
Sample ID:	PKM-M-20	Sample Name:	
Acquisition Date:	03/22/21 01:03:22 PM	Run Time(min):	0.00
Vial:	CStk1-01:11	Injection Volume(µL):	1.00


HRMS21I22MAR11 #33-66 RT: 0.25-0.50 AV: 34 SB: 1 0.01 NL: 1.55E6  
T: FTMS + c ESI Full ms [100.00-750.00]



HRMS of compound **6g**



$^1\text{H}$  NMR spectrum of **6h** (400MHz,CDCl<sub>3</sub>)




$^{13}\text{C}$  NMR spectrum of **6h** (100 MHz,  $\text{CDCl}_3$ )


## SAIF [HRMS Report]

Data File:	HRMS21I22MAR09	Original Data Path:	D:\INTERNAL NEW\2021\Mar 2021
Sample ID:	PKM-M-15R	Sample Name:	
Acquisition Date:	03/22/21 12:59:26 PM	Run Time(min):	0.00
Vial:	CStk1-01:9	Injection Volume(µl):	1.00


HRMS21I22MAR09 #33-67 RT: 0.25-0.50 AV: 35 SB: 1 0.01 NL: 8.96E6  
T: FTMS + c ESI Full ms [100.00-750.00]



HRMS of compound **6h**



$^1\text{H}$  NMR spectrum of **6i** (400MHz,  $\text{CDCl}_3$ )





$^{13}\text{C}$  NMR spectrum of **6i** (100 MHz,  $\text{CDCl}_3$ )


## SAIF [HRMS Report]

Data File:	HRMS21I22MAR10	Original Data Path:	D:\INTERNAL NEW\2021\Mar 2021
Sample ID:	PKM-M-16R	Sample Name:	
Acquisition Date:	03/22/21 01:01:25 PM	Run Time(min):	0.00
Vial:	CStk1-01:10	Injection Volume(μl):	1.00


HRMS21I22MAR10 #33-67 RT: 0.25-0.50 AV: 35 SB: 1 0.00 NL: 5.23E6  
T: FTMS + p ESI Full ms [150.00-1000.00]



HRMS of compound **6i**



<sup>1</sup>H NMR spectrum of **6j** (400MHz, CDCl<sub>3</sub>)




$^{13}\text{C}$  NMR spectrum of **6j** (100MHz,  $\text{CDCl}_3$ )


## SAIF [HRMS Report]

Data File:	HRMS21I23MAR10	Original Data Path:	D:\INTERNAL NEW\2021\Mar 2021
Sample ID:	PKM-M-24R	Sample Name:	
Acquisition Date:	03/23/21 11:48:40 AM	Run Time(min):	0.00
Vial:	CStk1-01:10	Injection Volume( $\mu$ l):	1.00


HRMS21I23MAR10 #33-66 RT: 0.25-0.50 AV: 34 SB: 1 0.01 NL: 4.39E6  
T: FTMS + c ESI Full ms [100.00-750.00]



HRMS of compound **6j**



$^1\text{H}$  NMR spectrum of **6k** (400MHz,  $\text{CDCl}_3$ )



$^{13}\text{C}$  NMR spectrum of **6k** (100MHz,  $\text{CDCl}_3$ )

## SAIF [HRMS Report]

Data File:

HRMS21I19MAR11

Original Data Path:

D:\INTERNAL NEW\2021\Mar  
2021

Sample ID:

PKM-M-27R

Sample Name:

Acquisition Date:

03/19/21 11:22:09 AM

Run Time(min):

Vial:



CStk1-01:11

0.00

Injection Volume( $\mu$ l):

HRMS21I19MAR11 #33-67 RT: 0.25-0.50 AV: 35 SB: 1 0.01 NL: 2.06E7


T: FTMS + c ESI Full ms [100.00-750.00]




$m/z$ : $[M+H]^+$ Calcd for  $C_{17}H_{25}N_2O_4$ : 321.1801;  
Found: 321.1807.

HRMS of compound **6k**





<sup>1</sup>H NMR spectrum of **6I** (400MHz, CDCl<sub>3</sub>)



$^{13}\text{C}$  NMR spectrum of **6I** (100 MHz,  $\text{CDCl}_3$ )

## SAIF [HRMS Report]

Data File:

HRMS21I23MAR11

Original Data Path:

D:\INTERNAL NEW\2021\Mar  
2021

Sample ID:

PKM-M-26R

Sample Name:

Acquisition Date:

03/23/21 11:50:41 AM

Run Time(min):

0.00



Vial:

CStk1-01:11

Injection Volume( $\mu$ l):


1.00

HRMS21I23MAR11 #33-66 RT: 0.25-0.50 AV: 34 SB: 1 0.01 NL: 2.34E6  
T: FTMS + c ESI Full ms [100.00-750.00]




m/z:  $[M + H]^+$  Calcd for:  $C_{21}H_{33}N_2O_4$  377.2435;  
Found: 377.2436.


HRMS of compound **6l**



<sup>1</sup>H NMR spectrum of **6m** (400MHz, CDCl<sub>3</sub>)




$^{13}\text{C}$  NMR spectrum of **6m** (100MHz,  $\text{CDCl}_3$ )




DEPT-135 spectrum of **6m** (100MHz, CDCl<sub>3</sub>)







2D-COSY spectrum of **6m** (400 MHz, CDCl<sub>3</sub>)



2D-HSQC spectrum of **6m** (400MHz, CDCl<sub>3</sub>)



<sup>1</sup>H NMR spectrum of **6n** (400MHz, CDCl<sub>3</sub>)




$^{13}\text{C}$  NMR spectrum of **6n** (100 MHz,  $\text{CDCl}_3$ )



## SAIF [HRMS Report]

Data File:	HRMS21I19MAR12	Original Data Path:	D:\INTERNAL NEW\2021\Mar 2021
Sample ID:	PKM-M-28R	Sample Name:	
Acquisition Date:	03/19/21 11:24:08 AM	Run Time(min):	0.00
Vial:	CStk1-01:12	Injection Volume(µl):	1.00


HRMS21I19MAR12 #32-65 RT: 0.25-0.50 AV: 34 SB: 1 0.01 NL: 3.23E6  
T: FTMS + c ESI Full ms [100.00-750.00]



HRMS of compound **6n**



<sup>1</sup>H NMR spectrum of **6o** (400MHz, CDCl<sub>3</sub>)





$^{13}\text{C}$  NMR spectrum of **6o** (100 MHz,  $\text{CDCl}_3$ )


### SAIF [HRMS Report]

Data File:	HRMS21I23MAR12	Original Data Path:	D:\INTERNAL NEW\2021\Mar 2021
Sample ID:	PKM-M-29R	Sample Name:	
Acquisition Date:	03/23/21 11:52:38 AM	Run Time(min):	0.00
Vial:	CStk1-01:12	Injection Volume(µl):	1.00


HRMS21I23MAR12 #32-63 RT: 0.25-0.50 AV: 32 SB: 1 0.00 NL: 1.23E5  
T: FTMS + p ESI Full ms [150.00-1000.00]



**Spectral data of 5a-5o**



$^1\text{H}$  NMR spectrum of **5a** (400 MHz,  $\text{CDCl}_3$ )





$^{13}\text{C}$  NMR spectrum of **5a** (100MHz, MHz,  $\text{CDCl}_3$ )

### SAIF [HRMS Report]


Data File:	HRMS21I23MAR08	Original Data Path:	D:\INTERNAL NEW\2021\Mar 2021
Sample ID:	PKM-M-22R	Sample Name:	
Acquisition Date:	03/23/21 11:44:45 AM	Run Time(min):	0.00
Vial:	CStk1-01:8	Injection Volume(µl):	1.00

HRMS21I23MAR08 #32-64 RT: 0.25-0.50 AV: 33 SB: 1 0.00 NL: 4.19E5  
T: FTMS + p ESI Full ms [150.00-1000.00]






$^1\text{H}$  NMR spectrum of **5b** (400MHz,  $\text{CDCl}_3$ )




$^{13}\text{C}$  NMR spectrum of **5b** (100MHz,  $\text{CDCl}_3$ )




$^1\text{H}$  NMR spectrum of **5c** (400 MHz,  $\text{CDCl}_3$ )







$^{13}\text{C}$  NMR spectrum of **5c** (100 MHz,  $\text{CDCl}_3$ )




$^1\text{H}$  NMR spectrum of **5d** (400MHz,  $\text{CDCl}_3$ )




$^{13}\text{C}$  NMR spectrum of **5d** (100MHz,  $\text{CDCl}_3$ )




$^1\text{H}$  NMR spectrum of **5e** (400 MHz,  $\text{CDCl}_3$ )




$^{13}\text{C}$  NMR spectrum of **5e** (100MHz,  $\text{CDCl}_3$ )




<sup>1</sup>H NMR spectrum of **5f** (400 MHz, CDCl<sub>3</sub>)




$^{13}\text{C}$  NMR spectrum of **5f** (100MHz,  $\text{CDCl}_3$ )




$^1\text{H}$  NMR spectrum of **5g** (400 MHz,  $\text{CDCl}_3$ )




$^{13}\text{C}$  NMR spectrum of **5g** (100MHz,  $\text{CDCl}_3$ )




<sup>1</sup>H NMR spectrum of **5h** (400MHz, CDCl<sub>3</sub>)




$^{13}\text{C}$  NMR spectrum of **5h** (100MHz,  $\text{CDCl}_3$ )




<sup>1</sup>H NMR spectrum of **5i** (400 MHz, CDCl<sub>3</sub>)



$^{13}\text{C}$  NMR spectrum of **5i** (100MHz,  $\text{CDCl}_3$ )




$^1\text{H}$  NMR spectrum of **5j** (400 MHz,  $\text{CDCl}_3$ )




$^{13}\text{C}$  NMR spectrum of **5j** (100MHz,  $\text{CDCl}_3$ )







$^1\text{H}$  NMR spectrum of **5k** (400MHz,  $\text{CDCl}_3$ )




$^{13}\text{C}$  NMR spectrum of **5k** (100MHz,  $\text{CDCl}_3$ )




$^1\text{H}$  NMR spectrum of **5I** (400 MHz,  $\text{CDCl}_3$ )




$^{13}\text{C}$  NMR spectrum of **5I** (100MHz,  $\text{CDCl}_3$ )




<sup>1</sup>H NMR spectrum of **5m** (400MHz, CDCl<sub>3</sub>)



$^{13}\text{C}$  NMR spectrum of **5m** (100MHz,  $\text{CDCl}_3$ )




$^1\text{H}$  NMR spectrum of **5n** (400MHz,  $\text{CDCl}_3$ )




170

$^{13}\text{C}$  NMR spectrum of **5n** (100MHz,  $\text{CDCl}_3$ )





<sup>1</sup>H NMR spectrum of **5o** (400MHz, CDCl<sub>3</sub>)



$^{13}\text{C}$  NMR spectrum of **5o** (100 MHz,  $\text{CDCl}_3$ )